¼ò
¤™
- ¼ò
- ·±
- EN
-
¹ØÓÚvic3308 ¤™
-
¿Æ¼¼Á¢Òì ¤™
-
²úÆ·ÓëÓªÒµ ¤™
-
ÐÂÎÅÖÐÐÄ ¤™
-
Ͷ×ÊÕß¹Øϵ ¤™
-
ESG ¤™
-
Ö°ÒµÉú³¤ ¤™
¼ò
¤™
ÏêϸÐÅÏ¢ÈçÏ£º
±¾´Î´ó»áµÄÑо¿Ð§¹ûÏÔʾ£¬£¬£¬£¬£¬×èÖ¹Êý¾Ý×èÖ¹ÈÕÆÚ£¨2025Äê6ÔÂ20ÈÕ£©£¬£¬£¬£¬£¬ HS-20089ÔÚδɸѡB7-H4±í´ïµÄÇéÐÎÏ£¬£¬£¬£¬£¬ÔÚ¾¶àÏßÖÎÁÆʧ°ÜµÄ²¬ÄÍÒ©Âѳ²°©£¨PROC£©»¼ÕßÖÐÕ¹ÏÖ³öÁîÈ˹ÄÎèµÄÁÆЧ¡£¡£¡£¡£¡£ÔÚËùÓнÓÊܹýHS-20089 4.8mg/kgÖÎÁƵÄPROC»¼ÕßÖУ¬£¬£¬£¬£¬ÖÐλËæ·Ãʱ¼äΪ11.5¸öÔ£¬£¬£¬£¬£¬È·ÈϵĿ͹ۻº½âÂÊ£¨ORR£©Îª48.5%£¬£¬£¬£¬£¬»º½âÒ»Á¬Ê±¼ä£¨DoR£©´ï6.8¸öÔ£»£»£»£»£»ÖÐλÎÞÏ£ÍûÉúÑÄÆÚ£¨mPFS£©Îª6.4¸öÔ£¬£¬£¬£¬£¬ÖÐλ×ÜÉúÑÄÆÚ£¨mOS£©Îª14.6¸öÔ¡£¡£¡£¡£¡£HS-20089×¢ÉäÒºµÄÇå¾²ÐÔÌØÕ÷ÓëIÆÚÑо¿Ð§¹ûÒ»Ö£¬£¬£¬£¬£¬Î´ÊӲ쵽¼äÖÊÐԷβ¡µÄÐźš£¡£¡£¡£¡£ÉÏÊöÁÙ´²Ñо¿Ð§¹ûÖ§³Ö¸ÃÒ©ÎïÔÚPROC»¼ÕßÖеĽøÒ»²½¿ª·¢£¬£¬£¬£¬£¬ÏÖÔÚÏà¹ØµÄ¢óÆÚÑо¿£¨NCT06855069)ÕýÔÚ¾ÙÐÐÖС£¡£¡£¡£¡£
¸ü¶àÑо¿ÐÅÏ¢£º¡¶ESMO | º²ÉÖÆÒ©HS-20089(B7-H4 ADC)ÓÃÓÚ²¬ÄÍÒ©Âѳ²°©£¨PROC£©»¼ÕßÖÎÁƵĢòÆÚÑо¿Ð§¹ûÐû²¼¡·¡£¡£¡£¡£¡£
¹ØÓÚHS-20089
HS-20089ÊÇÓɺ²ÉÖÆÒ©×ÔÖ÷Ñз¢µÄB7-H4°ÐÏòADC¡£¡£¡£¡£¡£×èÖ¹ÏÖÔÚ£¬£¬£¬£¬£¬HS-20089ÓÃÓÚÖÎÁÆÂѳ²°©Ë³Ó¦Ö¢ÒÑÔÚÖйú½øÈëIIIÆÚÁÙ´²Ñо¿½×¶Î£¬£¬£¬£¬£¬ÉÐÓÐÓÃÓÚÖÎÁÆ×Ó¹¬ÄÚĤ°©¼°ÆäËûʵÌåÁöµÄPoC¿´·¨ÑéÖ¤ÁÙ´²Ñо¿ÕýÔÚ¾ÙÐС£¡£¡£¡£¡£
2023Äê10Ô£¬£¬£¬£¬£¬º²ÉÖÆÒ©ÊÚÓè¸ðÀ¼ËØÊ·¿Ë¿ª·¢¡¢Éú²ú¼°ÉÌÒµ»¯HS-20089È«Çò¶ÀÍÌÔÊÐíȨÁ¦£¨²»º¬Öйú´ó½¡¢Ïã¸Û¡¢°ÄÃż°Ì¨ÍåµØÇø£©¡£¡£¡£¡£¡£GSK ÕýÔÚͨ¹ýÈ«Çò¿ª·¢ÍýÏëÍƽø GSK5733584£¬£¬£¬£¬£¬ÏÖÔÚÕýÔÚÈ«Çò¹æÄ£ÄÚ¾ÙÐÐµÄ I ÆÚÁÙ´²ÊÔÑ飬£¬£¬£¬£¬°üÀ¨ BEHOLD-1£¨NCT06431594£©ºÍ BEHOLD-2£¨NCT06796907£©Ñо¿¡£¡£¡£¡£¡£
2025Äê5Ô£¬£¬£¬£¬£¬HS-20089»ñNMPAÅú×¼ÄÉÈëÍ»ÆÆÐÔÖÎÁÆÒ©Î£¬£¬£¬£¬Öƶ©Ë³Ó¦Ö¢ÎªÓÃÓÚº¬²¬ÄÍÒ©¸´·¢ÉÏƤÐÔÂѳ²°©¡¢ÊäÂѹܰ©»òÔ·¢ÐÔ¸¹Ä¤°©»¼Õß¡£¡£¡£¡£¡£
¹ØÓÚÂѳ²°©
Âѳ²°©£¨OC£©ÊÇ×î³£¼ûµÄ¸¾¿Æ¶ñÐÔÖ×ÁöÖ®Ò»£¬£¬£¬£¬£¬2022Ä꣬£¬£¬£¬£¬È«ÇòÔ¼Õï¶Ï³ö324,603ÀýÂѳ²°©Ð²¡Àý£¬£¬£¬£¬£¬Ê¹Æä³ÉΪŮÐÔÖеڰ˴󳣼û¶ñÐÔÖ×Áö¡£¡£¡£¡£¡£¸ÃÄêÔ¼ÓÐ206,956ÀýÂѳ²°©éæÃü£¬£¬£¬£¬£¬Âѳ²°©³ÉΪŮÐÔ°©Ö¢Ïà¹ØéæÃüµÄµÚ°Ë´óÔµ¹ÊÔÓÉ¡£¡£¡£¡£¡£ÔÚÖйú£¬£¬£¬£¬£¬2022ÄêÂѳ²°©µÄ·¢²¡ÊýΪ61,060Àý£¬£¬£¬£¬£¬éæÃüÈËÊýΪ32,646Àý[1] ¡£¡£¡£¡£¡£
ÊÖÊõÍŽáÒÔ²¬Îª»ù´¡µÄ»¯ÁÆÊÇÏÖÔÚÂѳ²°©µÄ±ê×¼ÖÎÁÆ·½·¨£¬£¬£¬£¬£¬µ«¾ø´ó²¿·ÖÍíÆÚ»¼Õß»áÔÚ3ÄêÄÚ¸´·¢£¬£¬£¬£¬£¬²¢×îÖÕ»á¶Ô²¬À໯ÁƱ¬·¢ÄÍÒ©ÐÔ£¬£¬£¬£¬£¬²¬ÄÍÒ©¸´·¢Âѳ²°©£¨PROC£©µÄÁÙ´²ÖÎÁÆÊֶκÍÁÆЧ¾ùÊ®·ÖÓÐÏÞ¡£¡£¡£¡£¡£Æ¾Ö¤½üÄêÀ´¿ªÕ¹µÄ¢óÆÚËæ»ú±ÈÕÕÑо¿ÖеıÈÕÕ×飨·Ç²¬µ¥Ò©»¯ÁÆ£©Êý¾ÝÏÔʾ£¬£¬£¬£¬£¬·Ç²¬µ¥Ò©»¯ÁÆÂѳ²°©µÄ¿Í¹Û»º½âÂÊ£¨ORR£©½ö4%~15.9%£¬£¬£¬£¬£¬ÖÐλÎÞÏ£ÍûÉúÑÄÆÚ£¨mPFS£©½ö3.4~3.98¸öÔ¡£¡£¡£¡£¡£¹ØÓÚ½ÓÊܹý1ÖÁ2ÏßÖÎÁƵĻ¼Õߣ¬£¬£¬£¬£¬·Ç²¬»¯ÁÆÍŽᱴ·¥Öéµ¥¿¹µÄORRΪ27.3%£¬£¬£¬£¬£¬mPFSÑÓÉìÖÁ6.7¸öÔ£¬£¬£¬£¬£¬ÖÐλÉúÑÄÆÚ£¨mOS£©µÖ´ï16.6¸öÔ¡£¡£¡£¡£¡£Ö»¹ÜPFSÏÔÖøÑÓÉ죬£¬£¬£¬£¬µ«OSÓë·Ç²¬»¯ÁÆÏà±ÈÎÞÏÔ×Å»ñÒæ[2-6] ¡£¡£¡£¡£¡£ÏÖÔڸü²²¡ÈÔ±£´æÖØ´óδ±»Öª×ãµÄÁÙ´²ÐèÇ󣬣¬£¬£¬£¬Ø½´ýÑ°ÕÒ¸üΪÓÐÓõÄÖÎÁÆ·½·¨¡£¡£¡£¡£¡£
¹ØÓÚIGCS 2025
µÚ24½ì¹ú¼Ê¸¾¿ÆÖ×ÁöлáÈ«ÇòÄê»á£¨IGCS 2025£©ÓÚ 2025Äê11ÔÂ5ÈÕÖÁ7ÈÕÔÚÄÏ·Ç¿ªÆնصÄÊÀ¼Í³Ç¾Û»áÖÐÐľÙÐУ¬£¬£¬£¬£¬²Î»áÖ°Ô±°üÀ¨¸¾¿ÆÖ×Áöѧ¼Ò¡¢Ö×Áö¿ÆÒ½Éú¡¢¿Æѧ¼ÒµÈÖÚ¶àÏà¹ØÁìÓòÈËÊ¿¡£¡£¡£¡£¡£»£»£»£»£¾Û»áÄÚÈݸ»ºñ£¬£¬£¬£¬£¬º¸Ç¸¾¿ÆÖ×Áöѧ¸÷·½Ã棬£¬£¬£¬£¬×÷ΪÊ×´ÎÔÚ·ÇÖÞ´ó½¾ÙÐеÄÈ«Çò IGCS ¾Û»á£¬£¬£¬£¬£¬ÎªÓë¸÷ѧ¿Æ¶¥¼âר¼Ò½»Á÷ÌṩÁËÆæÒìʱ»ú£¬£¬£¬£¬£¬Íƶ¯¸¾¿ÆÖ×ÁöѧÑо¿Óëʵ¼ùÉú³¤¡£¡£¡£¡£¡£
²Î¿¼ÎÄÏ×£º
[1]International Agency for Research on Cancer. (2024). Cancer TODAY: GLOBOCAN 2022 (version 1.1). Retrieved April 26, 2025, from Global Cancer Observatory
[2]Pujade-Lauraine E, Fujiwara K, Ledermann JA, et al. Lancet Oncol. Jul 2021;22(7):1034-1046.
[3] Gaillard S, Oaknin A, Ray-Coquard I, et al. Gynecol Oncol. Nov 2021;163(2):237-245.
[4] Hamanishi J, Takeshima N, Katsumata N, et al. J Clin Oncol. Nov 20 2021;39(33):3671-3681.
[5] Pujade-Lauraine E, Hilpert F, Weber B, et al.
[6] Moore KN, Angelergues A, Konecny GE, et al. N Engl J Med. Dec 7 2023;389(23):2162-2174.
¹ØÓÚº²ÉÖÆÒ©
ÃâÔðÉùÃ÷
Ç°Õ°ÐÔ˵Ã÷
